

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Atty 01579-0861

Dkt.

C# M#

SEMPOWSKI et al



C/A.U.

1646

Serial No. 10/673,667

Examiner: Xie, X.

Filed: September 30, 2003

Date: September 18, 2006

Title: THYMIC ATROPHY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add  
\$360.00 (1203)/\$0.00 (2203) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s)

One Month Extension \$120.00 (1251)/\$0.00 (2251)  
Two Month Extensions \$450.00 (1252)/\$0.00 (2252)  
Three Month Extensions \$1020.00 (1253)/\$0.00 (2253)  
Four Month Extensions \$1590.00 (1254)/\$0.00 (2254)  
Five Month Extensions \$2160.00 (1255)/\$1080.00 (2255) \$

Terminal disclaimer enclosed, add \$130.00 (1814)/ \$0.00 (2814) \$

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$ 0.00

Assignment Recording Fee \$40.00 (8021) \$ 0.00

Other: \$ 0.00

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor  
Arlington, Virginia 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:at

NIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SEMPOWSKI et al

Serial No. 10/673,667

Filed: September 30, 2003

For: THYMIC ATROPHY

Confirmation No. 2031

Atty. Ref.: 01579-0861

Group: 1646

Examiner: Xie, X.

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 18, 2006

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-SB/08a Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-SB/08a together with copies of each identified document (as may be required) and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:


- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

SEMPOWSKI et al  
Appl. No. 10/673,667

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Mary J. Wilson

Reg. No. 32,955

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

Atty. Docket No.

Serial No.

INFORMATION DISCLOSURE  
CITATION

01579-0861

10/673,667

Applicant

(Use several sheets if necessary)


SEMPOWSKI et al

Filing Date

TC/A.U.

SEP 18 2006

September 30, 2003



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Oberholzer et al, "Apoptosis in sepsis: a new target for therapeutic exploration", FASEB J. 15:879-892 (2001)
	Watanobe and Suda, "A significant role of leukemia inhibitory factor in the brain and periphery in endotoxin stimulation of adrenocorticotropin secretion in the rat", Brain Research 865:97-101 (2000)
	Tanaka et al, "Identification of leukemia inhibitory factor as a potent mast cell growth-enhancing factor produced by mouse keratinocyte cell line, KCMH-1", Arch. Dermatol. Res. 293:18-25 (2001)
	Metcalf and Gearing, "Fatal Syndrome in Mice Engrafted with Cells Producing High Levels of the Leukemia Inhibitory Factor", Proceedings of the National Academy of Sciences of the United States of America 86(15):5948-5952 (1989)
	Villers et al, "Increased Plasma Levels of Human Interleukin for DA1.a Cells/Leukemia Inhibitory Factor in Sepsis Correlate with Shock and Poor Prognosis", The Journal of Infectious Diseases 171:232-236 (1995)
	Burg et al, "Leukaemia Inhibitory Factor Derived From Rat Colon Carcinoma Cells Increases Host Susceptibility to Tumour Growth", Cytokine 7(8):784-792 (1995)
	Liu et al, "Expression of leukemia-inhibitory factor as an autocrine growth factor in human medulloblastomas", J. Cancer Res. Clin. Oncol 125:475-480 (1999)
	Meisel et al, "Leukaemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: a gp130-mediated mechanism", British Journal of Haematology 107:747-755 (1999)
	Jansen et al, "Release of Leukemia Inhibitory Factor in Primate Sepsis; Analysis of the Role of TNF- $\alpha$ ", The Journal of Immunology 156:4401-4407 (1996)
	Sempowski et al, "Leukemia Inhibitory Factor, Oncostatin M, IL-6, and Stem Cell Factor mRNA Expression in Human Thymus Increases with Age and Is Associated with Thymic Atrophy", The Journal of Immunology 164:2180-2187 (2000)
	Oberholzer et al, "Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis", PNAS 98(20):11503-11508 (2001)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.